MedTrace Logo

Antihypertensive Efficacy of Fixed Combination Drug

NCT01211314 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-06-28

No results posted yet for this study

Summary

Treatment and control of hypertension is still insufficient. About 50% of the patients remain uncontrolled. Lack of compliance with discontinuation of drug treatment is an important reason for not achieving blood pressure. Several studies have shown that use of fixed combinations improve compliance significantly, by reducing the number of pill's intake.

This study will assess the antihypertensive efficacy of Vasodip-Combo 20® \[enalapril 20 mg + lercanidipine 10 mg\] as a fixed combination drug in uncontrolled antihypertensive patients.

Conditions

Interventions

DRUG

Lercanidipine/enalapril fixed combination

Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study

Sponsors & Collaborators

  • Dexcel Pharma Technologies Ltd.

    collaborator INDUSTRY

  • Meir Medical Center

    lead OTHER

Principal Investigators

  • Eduardo Podjarny, MD · Clalit Health Services

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-12-31
Completion
2012-04-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01211314 on ClinicalTrials.gov